MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.57 -7.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.56

Max

1.7

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+137.06% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	3.6M 498M
Eelmine avamishind	9.22
Eelmine sulgemishind	1.57

Uudiste sentiment

By Acuity

60%

40%

292 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. jaan 2026, 23:49 UTC

Kuumad aktsiad

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

26. jaan 2026, 23:09 UTC

Suurimad hinnamuutused turgudel

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

26. jaan 2026, 23:52 UTC

Market Talk

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

26. jaan 2026, 23:46 UTC

Market Talk

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

26. jaan 2026, 23:37 UTC

Market Talk

Gold Rises Amid Concerns Over Tariffs -- Market Talk

26. jaan 2026, 22:41 UTC

Market Talk

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

26. jaan 2026, 22:26 UTC

Tulu

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

26. jaan 2026, 22:26 UTC

Tulu

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

26. jaan 2026, 22:25 UTC

Tulu

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

26. jaan 2026, 22:25 UTC

Tulu

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

26. jaan 2026, 22:25 UTC

Tulu

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

26. jaan 2026, 22:24 UTC

Tulu

Karoon Energy 4Q Sales Revenue US$156.1 Million

26. jaan 2026, 22:23 UTC

Tulu

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

26. jaan 2026, 22:23 UTC

Tulu

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

26. jaan 2026, 22:23 UTC

Tulu

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

26. jaan 2026, 22:22 UTC

Tulu

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

26. jaan 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Copper Shareholders Approve Takeover

26. jaan 2026, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

26. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

26. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. jaan 2026, 21:34 UTC

Tulu

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

26. jaan 2026, 21:34 UTC

Tulu

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

26. jaan 2026, 21:34 UTC

Tulu

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

26. jaan 2026, 21:34 UTC

Tulu

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

26. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Sales $7.69B >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Net $378M >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q EPS $1.64 >NUE

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

137.06% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 137.06%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

292 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.